huahaipharm(SH:600521) Zheng Quan Zhi Xing·2025-07-02 16:18Summary of Key Points Core Viewpoint - The announcement details the conversion results of Zhejiang Huahai Pharmaceutical Co., Ltd.'s convertible bonds, indicating minimal conversion activity and a significant amount of unconverted bonds remaining. Group 1: Convertible Bond Conversion Status - As of June 30, 2025, a total of 182,000 yuan of Huahai convertible bonds have been converted into 5,304 shares, representing 0.00036% of the company's total shares before conversion [1][6] - The amount of unconverted Huahai convertible bonds stands at 1,842,417,000 yuan, accounting for 99.9901% of the total issuance [1][6] - No conversions occurred during the period from April 1, 2025, to June 30, 2025 [5][6] Group 2: Convertible Bond Issuance Overview - Huahai issued 18.426 million convertible bonds on November 2, 2020, with a total value of 184,260,000 yuan and a maturity of six years [2] - The initial conversion price was set at 34.66 yuan per share, which has undergone several adjustments, with the latest adjustment bringing it to 33.31 yuan per share effective June 17, 2025 [2][5] Group 3: Share Capital Changes - The company repurchased and canceled 10,656,753 shares, resulting in a reduction of total share capital [6][7] - The total number of shares after the cancellation is 1,497,251,081 shares [6][7]